Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Villingen-Schwenningen

47 clinical trials in Villingen-Schwenningen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Villingen-Schwenningen at a glance
47
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

47 trials in Villingen-Schwenningen

Open in trial search

Obesity+1

Recruiting

Phase 3 Extension Trial Evaluating Long‑Term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
  • Sponsor:Novo Nordisk A/S

Cardiovascular disorder+1

Recruiting

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Arteriosclerosis

Recruiting

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Arteriosclerosis

Recruiting

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC

Type 2 diabetes mellitus

Recruiting

Zenagamtide versus semaglutide: a study of blood sugar and weight reduction in adults with type 2 diabetes inadequately controlled on metformin and/or SGLT2 inhibitor

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Glomerulonephritis membranoproliferative+1

Recruiting

Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Plasma cell myeloma

Recruiting

Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Hodgkin's disease

Recruiting

A Study of Pembrolizumab and Radiotherapy for Patients with Early-Stage Favorable Classic Hodgkin Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:University Of Cologne

IgA nephropathy

Recruiting

Study of felzartamab compared to placebo in adults with IgA nephropathy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Biogen Idec Research Limited

Study of ELA026 for Treatment of Secondary Hemophagocytic Lymphohistiocytosis in Patients with Lymphoma Who Have Not Received Previous Treatment

Recruiting
InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:ELA026
  • Sponsor:Electra Therapeutics Inc.

COVID-19

Recruiting

Study of ibuzatrelvir alone or combined with remdesivir in adults with COVID-19 who have severely compromised immune systems

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ibuzatrelvir
  • Sponsor:Pfizer Inc.

Other cities in Germany

The busiest research cities in the country

All 513 cities in Germany

Clinical research in Villingen-Schwenningen

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on innovative treatments for various cancers, including colon cancer, lymphoma, and multiple myeloma. Studies evaluate new therapeutic approaches and drug combinations to improve patient outcomes.

  • Preoperative chemotherapy for advanced colon cancer
  • Novel therapies for B-cell non-Hodgkin lymphoma
  • Treatment strategies for multiple myeloma

Research includes evaluation of targeted therapies and immunotherapy approaches for better treatment efficacy.

02 Nephrology Studies

Extensive research into kidney diseases, particularly IgA Nephropathy and related conditions. Multiple trials are investigating novel therapeutic agents to preserve kidney function and reduce disease progression.

  • Treatment of IgA Nephropathy
  • Chronic kidney disease management
  • Proteinuria reduction strategies

Studies focus on innovative treatments and their impact on kidney function preservation.

03 Metabolic Disorders

Research centered on treating metabolic conditions, including Type 2 Diabetes and obesity. Trials evaluate new medications' effectiveness in managing these chronic conditions.

  • Cardiovascular outcomes in diabetes treatment
  • Weight management therapies
  • Metabolic disease interventions

Studies aim to improve patient outcomes through innovative therapeutic approaches.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.